---
title: "H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289477645.md"
description: "H.C. Wainwright analyst Ram Selvaraju reaffirmed a Buy rating on NervGen Pharma (NGEN) with an $18.00 price target, outperforming the market consensus of a Strong Buy with an $11.90 average target. Selvaraju, known for strong performance in the healthcare sector, maintains his bullish stance on the stock."
datetime: "2026-06-11T13:46:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289477645.md)
  - [en](https://longbridge.com/en/news/289477645.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289477645.md)
---

# H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)

H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on NervGen Pharma on June 8 and set a price target of $18.00.

### Introducing TipRanks MCP for Agents

-   Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
-   Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Aclaris Therapeutics, and Urogen Pharma. According to TipRanks, Selvaraju has an average return of 16.9% and a 48.51% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for NervGen Pharma with a $11.90 average price target.

### Related Stocks

- [NGEN.US](https://longbridge.com/en/quote/NGEN.US.md)
- [EBS.US](https://longbridge.com/en/quote/EBS.US.md)
- [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md)
- [URGN.US](https://longbridge.com/en/quote/URGN.US.md)

## Related News & Research

- [Meet the Gen Z AI whiz at the center of a hedge fund meltdown](https://longbridge.com/en/news/294425537.md)
- [How investors can navigate the healthcare sector](https://longbridge.com/en/news/293960711.md)
- [Truist Financial Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)](https://longbridge.com/en/news/293930009.md)
- [Northland Securities Keeps Their Buy Rating on Rezolve AI (RZLV)](https://longbridge.com/en/news/294092952.md)
- [Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)](https://longbridge.com/en/news/293777709.md)